| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.05 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | 0.32 | 0.05 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.06 |